DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

AZN·AstraZeneca plc

$.
+. (+.%)
High
$189.12
Open
$188.26
Market Cap
215.82B
52W High
$15,730.00
Low
$187.51
P. Close
$187.03
P/E
28.02
52W Low
$10,104.00
Fwd P/E
147.31
Mean Target
-
Technical Score (1D)
64
BUY
News Sentiment
72
BULLISH
AstraZeneca and Daiichi Sankyo have secured a positive recommendation from the European Medicines Agency's CHMP for Enhertu, supporting its approval as a monotherapy for unresectable or metastatic HER2-positive solid tumors in adults with prior treatment. This opinion, based on Phase II data demonstrating meaningful responses across various tumor types, could position Enhertu as the first tumor-agnostic HER2-targeted therapy and ADC in the EU. Concurrently, the FDA has approved Datopotamab deruxtecan (Datroway) for an expanded indication in breast cancer, offering a new therapeutic option for patients. These developments underscore the continued progress in AstraZeneca's oncology pipeline, particularly in antibody-drug conjugates. Investors will be watching for the formal EU approval of Enhertu and the market uptake of Datroway in its expanded breast cancer indication.
Earnings Summary
AstraZeneca PLC is a global biopharmaceutical company engaged in the research, development, production, and commercialization of prescription medicines across key therapeutic areas including oncology, cardiovascular, renal and metabolism, and respiratory & immunology. Operating within the Healthcare sector, specifically the Drug Manufacturers - General industry, AstraZeneca focuses on delivering innovative treatments to patients worldwide through strategic partnerships and direct engagement with healthcare professionals. The company's recent quarterly performance shows a mixed pattern of exceeding or meeting analyst expectations for Earnings Per Share (EPS). In Q3 2025, AZN reported EPS of $1.19, surpassing the estimate of $1.13, with revenue at $15.19 billion. This followed Q2 2025, where EPS was $1.085 against an estimate of $1.46, and revenue was $14.46 billion. Prior to this, Q1 2025 saw EPS of $1.245, beating the estimate of $1.12, with revenue at $13.59 billion, and Q4 2024 reported EPS of $1.045, slightly above the estimate of $1.04, with revenue at $14.89 billion. Revenue has shown a general upward trend across the reported quarters, with Q1 2025 revenue at $13.59 billion, Q2 2025 at $14.46 billion, Q3 2025 at $15.19 billion, and projected Q1 2026 revenue at $15.36 billion, and Q2 2026 at $15.94 billion. Historically, AstraZeneca has demonstrated consistent revenue growth, with recent quarters generally showing year-over-year increases, driven by its key drug portfolios. The company has a track record of meeting or beating analyst EPS estimates in most of the recent quarters, with a notable beat in Q1 2025 and Q3 2025, and a slight beat in Q4 2024, though Q2 2025 saw a miss. Recent news highlights positive developments for Enhertu, with a recommendation for approval in the EU for unresectable or metastatic HER2-positive solid tumors, and expanded indications for Datopotamab deruxtecan in breast cancer, underscoring progress in its oncology pipeline. The company also reported strong Q1 revenue growth driven by its Oncology and Rare Disease segments and reaffirmed its 2026 guidance. Investors will be watching for the formal EU approval of Enhertu and the market uptake of Datroway, as well as continued performance updates from the Oncology and Rare Disease portfolios, and the company's ability to meet its mid-to-high single-digit revenue and low double-digit EPS growth targets for 2026.

EPS

EstBeatMiss
$0.97$1.11$1.25$1.39$1.53Q4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$1.22 - -
Q3'25$1.13$1.19+4.9%
Q2'25$1.46$1.08-25.9%
Q1'25$1.12$1.25+11.6%
Q4'24$1.04$1.04+0.8%

Revenue

EstBeatMiss
$13.3B$13.9B$14.5B$15.1B$15.6BQ4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$15.4B - -
Q3'25 - $15.2B -
Q2'25 - $14.5B -
Q1'25 - $13.6B -
Q4'24 - $14.9B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AZN Stock Snapshot

AZN is currently trading at $188.05, giving AstraZeneca plc a market cap of 215.82B and a P/E ratio of 28.0. Today's range spans $187.51–$189.12, with shares opening at $188.26 and moving up $1.02 (0.5%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 72/100.

Over the past year AZN has traded between $10104.00 and $15730.00 - the current price is -98.1% off the 52-week low and -98.8% from the high.

The technical picture for AZN is mixed - score 64/100, HOLD, with the stock at $188.05 (near 52-week lows) and sentiment bullish at 72/100. For a large-cap in Healthcare with 215.82B in capitalization The current P/E ratio stands at 28.0., this is a fairly common pre-earnings or pre-macro-event posture. Annual range: $10104.00–$15730.00. Neutral signals at this size often resolve sharply once a catalyst provides directional conviction.

Portfolio construction in Healthcare often uses large-cap names like AZN as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 64/100 (HOLD) at $188.05 (near 52-week lows) and bullish sentiment (72/100) frame the position as a catalyst play within the $10104.00–$15730.00 annual range rather than a directional bet.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…